Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021.
Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival.
Team members work in medical strategy, research & development, software development, medical imaging discovery and operations. Laurent Domas, Terumos’ VP of global interventional oncology strategy and therapy development, will lead the team as it develops solutions for people with cancer.
Terumo’s therapeutic interventional oncology portfolio includes drug-eluting microspheres (LifePearl microspheres), selective internal radiation therapy solutions with its Holmium platform (QuiremSpheres microspheres, QuiremScout microsphers and the QSuite software) and thermal microwave ablation with TATO.
Utilizing the new organizational set-up, Terumo plans to accelerate the commercial deployment of these offerings in the EMEA region while expanding the availability of the Holmium platform in other regions, including the U.S. and China. The group will also look to innovate in new, targeted drug-delivery solutions.
“With this team of specialists, we want to provide excellence in developing Interventional Oncology solutions to improve the clinical benefit for patients with cancer, and thus contribute to society through healthcare,” Domas said in the release.
